Research Article

A new luciferase immunoprecipitation system assay provided serological evidence for missed diagnosis of severe fever with thrombocytopenia syndrome

Shengyao Chen a,c, Minjun Xu d, Xiaoli Wu a, Yuan Bai a, Junming Shi a, Min Zhou a, Qiaoli Wu a, Shuang Tang a, Fei Deng a,* Bo Qin b,d,**, Shu Shen a,***

a State Key Laboratory of Virology and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China
b Shaoxing Women and Children's Hospital, No. 305 East Street Road, Shaoxing, 312000, China
c University of Chinese Academy of Sciences, Beijing, 100049, China
d Shaoxing People's Hospital, Zhejiang University School of Medicine, Shaoxing, 312000, China

ARTICLE INFO

Keywords:
Severe fever with thrombocytopenia syndrome (SFTS)
Severe fever with thrombocytopenia syndrome virus (SFTSV)
Luciferase immunoprecipitation systems (LIPS)
Shaoxing
Serological evidence
Missed diagnosis

ABSTRACT

Severe fever with thrombocytopenia syndrome (SFTS), caused by SFTS virus (SFTSV) infection, was first reported in 2010 in China with an initial fatality of up to 30%. The laboratory confirmation of SFTSV infection in terms of detection of viral RNA or antibody levels is critical for SFTS diagnosis and therapy. In this study, a new luciferase immunoprecipitation system (LIPS) assay based on pREN2 plasmid expressing SFTSV NP gene and tagged with Renilla luciferase (Rluc), was established and used to investigate the levels of antibody responses to SFTSV. Totally 464 serum samples from febrile patients were collected in the hospital of Shaoxing City in Zhejiang Province in 2019. The results showed that 82 of the 464 patients (17.7%) had antibody response to SFTSV, which were further supported by immuno-fluorescence assays (IFAs). Further, qRT-PCR and microneutralization tests showed that among the 82 positive cases, 15 patients had viremia, 10 patients had neutralizing antibody, and one had both (totally 26 patient). However, none of these patients were diagnosed as SFTS in the hospital probably because of their mild symptoms or subclinical manifestations. All the results indicated that at least the 26 patients having viremia or neutralizing antibody were the missed diagnosis of SFTS cases. The findings suggested the occurrence of SFTS and the SFTS incidence were higher than the reported level in Shaoxing in 2019, and that LIPS may provide an alternative strategy to confirm SFTS infection in the laboratory.

1. Introduction

The Severe fever with thrombocytopenia syndrome (SFTS) disease caused by SFTS virus (SFTSV) infection was first reported in China in 2010 with an initial fatality rate of up to 30% (Yu et al., 2011). The major clinical signs of SFTS include high fever and severe thrombocytopenia, accompanied with gastrointestinal symptoms, respiratory symptoms, neurologic symptoms, and hemorrhagic manifestations (Xiong et al., 2016). As of 2019, 25 provinces in China have reported over 13,000 SFTS cases to the National Notifiable Disease Reporting System including the laboratory-confirmed and probable cases. The seven provinces locating in the Eastern and Central China including Henan, Shandong, Anhui, Hubei, Liaoning, Zhejiang, and Jiangsu reported 99.3% of the total cases, with the highest laboratory confirmation rates of 100% occurring in Zhejiang and Jiangsu (Huang et al., 2021).

SFTSV belongs to the genus Bandavirus in the family Phenuiviridae, the genome of which is composed of three RNA segments (S, M and L). The S segment encodes nucleoprotein (NP) and non-structure protein NSs; the M segment encodes glycoprotein (GP) which would be cleaved into Gc and Gn proteins during maturation process of viral particles; and the L segment encodes RNA-depend RNA polymerase (RdRp) which is critical for RNA transcription. Identification of SFTSV infections is critical for the diagnosis of SFTS. According to guidelines issued in 2010 by the National Health Commission of the People's Republic of China for the prevention
and treatment of SFTS (http://www.gov.cn/gzdt/2010-10/09/content_1718261.htm), SFTSV infections can be laboratory confirmed using reverse transcription polymerase chain reaction (RT-PCR) to amplify SFTSV RNA or via subculture of patient serum samples to isolate virus. The guidelines also stated that detection of serological response specific to SFTSV is also an effective method to identify SFTSV infection. Seroconverted patients with anti-SFTSV IgG levels or neutralization activity four times higher than those during the acute stage are considered to have a recent SFTSV infection. The presence of total anti-SFTSV antibodies detected using double-antigen sandwich ELISA can also be used to confirm SFTSV exposure.

In this study, a new method for serological assay to determine the levels of total antibodies against SFTSV was established based on the luciferase immunoprecipitation system (LIPS). LIPS is a fluid-phase immunoassay which has been used for measuring antoantibodies in a wide range of autoimmune studies and antibodies against infectious agents including fungi, bacteria, and virus (Burbelo et al., 2015). This assay was applied to investigate the serological response to SFTSV among the febrile patients in Shaoxing City located in Zhejiang Province in 2019. Moreover, the epidemic features were characterized according to the results of LIPS assay and other laboratory tests using the patients’ serum samples. The results revealed the occurrence of SFTSV infection in Shaoxing and suggested the presence of missed diagnosis of SFTS cases probably due to the subclinical manifestations. Our findings further suggested that LIPS assay could be an alternative strategy to identify SFTSV infection in laboratory.

2. Materials and methods

2.1. Cell, virus, and antibodies

African green monkey kidney (Vero) cells (ATCC, CCL-81, Lot#: 60150897), Human embryonic kidney (HEK293T) cells (ATCC, CRL-11268, Lot#: 62296864) were purchased from the American type culture collection and were cultured by using Dulbecco’s Modified Eagle's Medium-High glucose (DMEM, NZK biotech, Wuhan, China) with 10% fetal bovine serum (FBS, Gibco, Australia). SFTSV strain HBGS13 was isolated from the serum sample of an SFTS patient in Hubei Province (Zhang et al., 2017) and was preserved in National Virus Resource Center (IVCAS 6.6312, NVRC, Wuhan, China).

The rabbit polyclonal antibodies against SFTSV nucleoprotein (NP) (anti-SFTSV NP) were prepared in the laboratory (Zhang et al., 2017; Shen et al., 2018). The Goat anti-Human IgG H&L (FITC) (abcam, Shanghai, China), the Goat anti-Human IgM H&L (FITC) (abcam), and the Goat anti-Rabbit IgG H&L (Alexa Fluor® 488) (abcam) were used as the secondary antibodies in IFA tests. The anti-FLAG Tag antibody (Sangon Biotech, Shanghai, China) was used as primary antibody in verifying expression of LIPS-related fusion protein. The Goat anti-Rabbit IgG (H + L) conjugated with horseradish peroxidase (HRP) (Proteintech, Wuhan, China) was used as the secondary antibody to verify expression of LIPS-related fusion protein.

2.2. Collection of serum samples from febrile patients and healthy persons

A total of 464 serum samples from febrile patients (≥37.3 °C in Shaoxing City, Zhejiang Province were collected during April to June (223 samples numbered from A1 to A223) and August to October (241 samples numbered from B1 to B241) in Shaoxing People’s Hospital in 2019. Infection with HIV, HBV, HCV and epidemic hemorrhagic fever-related pathogens was excluded by nosocomial tests. The personal information of these febrile patients including gender, age, and clinical parameters was summarized as shown in Table 1. The serum samples from 10 febrile patients positive for Tamdy virus (TAMV, genus Orthobunyaviridae) were transfected into HEK293T cells using Lipofectamine™ 3000 and were transfected into HEK293T cells using Lipofectamine™ 3000 and were transfected into HEK293T cells using Lipofectamine™ 3000

| Characteristics | Febrile patients (n = 464) | Healthy Donors (n = 30) |
|-----------------|--------------------------|------------------------|
| **Gender**      | Male: 251, 54.1%         | 15, 50%                |
|                 | Female: 213, 45.9%       | 15, 50%                |
| **Age, Median (IQR)** | 65 (54–76)               | 29 (25–35)             |
| **Clinical manifestation** | Fever: 464, 100%         | 0                      |
|                 | PLT (100–300×10^9/L), Median (IQR) | 182 (134–226)         | N/A                   |
|                 | WBC (4–10×10^9/L), Median (IQR) | 6.03 (4.68–9.71)       | N/A                   |
| **Laboratory Findings** | Viremia: 16, 3.4%       | N/A                    |
|                 | LIPS Test (anti-NP)      | 82, 18.7%              | 0                     |
|                 | MNT*                     | 11, 2.4%               | N/A                   |

Table 1: Personal information, clinical parameters, and results of laboratory tests from the febrile patients and healthy persons in this study.

The rabbit polyclonal antibodies against SFTSV nucleoprotein (NP) (anti-SFTSV NP) were prepared in the laboratory (Zhang et al., 2017) and was preserved in National Virus Resource Center (IVCAS 6.6312, NVRC, Wuhan, China) and was preserved in National Virus Resource Center (IVCAS 6.6312, NVRC, Wuhan, China) and was preserved in National Virus Resource Center (IVCAS 6.6312, NVRC, Wuhan, China) and was preserved in National Virus Resource Center (IVCAS 6.6312, NVRC, Wuhan, China). The plasmid transfected HEK 293T cells or SFTSV-infected Vero cells were fixed with 4% paraformaldehyde about 15 min, and permeabilized by 0.2% Triton-X 100 for 15 min at room temperature. After three washes with phosphate buffer saline (PBS, pH = 7.2), cells were blocked in PBS containing 5% (w/v) bovine serum albumin (BSA, BioFrox, Germany) at 37 °C for 1 h. Then, cells were incubated with human serum samples (1:20 dilution in PBS containing 1% BSA), the anti-SFTSV NP polyclonal antibody (1:1000), or the anti-Flag tag antibody (1:1000) as primary antibodies at 4 °C overnight. After three washes, cells were incubated with the Goat anti-Human IgG H&L (FITC), the Goat anti-Human IgM H&L (FITC) and the Goat anti-Rabbit IgG H&L (Alexa Fluor® 488) respectively, according to manufacturer’s instruction. Finally, fluorescence was visualized and images were taken using an inverted fluorescence microscope.

Western blot was used to verify expression of SFTSV NP in fusion with Flag-tag in the plasmid-transfected cells. The anti-FLAG tag or anti-SFTSV-NP rabbit polyclonal antibody (1:1000 dilution) were used as the primary antibody, HRP-conjugated goat anti-Rabbit IgG (H + L) (1:3000 dilution) were used as the secondary antibody.

2.3. Quantitative real-time PCR (qRT-PCR)

Total RNA was purified from the human serum sample (100 μL for each sample) by using TRIzol (NZK biotech, Wuhan, China) according to the manufacturer’s instruction, then subpackaged and deposited at −80 °C until further experiments. The viral RNA loads were determined by qRT-PCR as previously described (Zhu et al., 2019) by using the commercial one step TB Green® PrimeScript™ PLUS RT-PCR kit (Perfect Real Time) (TAKARA, Japan).

2.4. Immunofluorescence assay (IFA) and Western blot

The plasmid transfected HEK 293T cells or SFTSV-infected Vero cells were fixed with 4% paraformaldehyde about 15 min, and permeabilized by 0.2% Triton-X 100 for 15 min at room temperature. After three washes with phosphate buffer saline (PBS, pH = 7.2), cells were blocked in PBS containing 5% (w/v) bovine serum albumin (BSA, BioFrox, Germany) at 37 °C for 1 h. Then, cells were incubated with human serum samples (1:20 dilution in PBS containing 1% BSA), the anti-SFTSV NP polyclonal antibody (1:1000), or the anti-Flag tag antibody (1:1000) as primary antibodies at 4 °C overnight. After three washes, cells were incubated with the Goat anti-Human IgG H&L (FITC), the Goat anti-Human IgM H&L (FITC) and the Goat anti-Rabbit IgG H&L (Alexa Fluor® 488) respectively, according to manufacturer’s instruction. Finally, fluorescence was visualized and images were taken using an inverted fluorescence microscope.

Western blot was used to verify expression of SFTSV NP in fusion with Flag-tag in the plasmid-transfected cells. The anti-FLAG tag or anti-SFTSV-NP rabbit polyclonal antibody (1:1000 dilution) were used as the primary antibody, HRP-conjugated goat anti-Rabbit IgG (H + L) (1:3000 dilution) were used as the secondary antibody.
Transfection Reagent (Invitrogen, America). At 48 h post transfection, cells were harvested and lysed for luciferase assay directly or stored at −80 °C until further experiments. Luciferase assays were performed as previously described (Burbelo et al., 2019). Briefly, transfected cells were lysed on ice for 20 min, followed by cell disruption using an Ultrasound cell disruptor (Sonics, America) for 3 min. The lysis was diluted and prepared for each test having 10^7 light units (LU) per 10 μL. Serum samples were 1:50 diluted in Buffer A (20 mmol/L Tris, pH 7.5; 150 mmol/L NaCl; 5 mmol/L MgCl2; 1% Triton X 100). For the LIPS test of each sample, a mixture of 90 μL diluted serum/plasma sample, 10 μL cell lysis containing viral antigen, and 7 μL 30% Pierce Protein A/G UltraLink Resin beads (Thermo Fisher Scientific, Waltham, MA) was prepared and thoroughly blended at 4 °C for 2 h. Then, beads were washed six times with Buffer A and two times with phosphate buffered solution (PBS). The light units of each test were measured using Renilla-Lumi™ Plus Luciferase Assay Kit (Beyotime, Shanghai, China). The cut-off value of light units was set as the average value of control samples plus triple its standard deviation. Febrile patients tested positive for SFTSV antibody by LIPS was listed in Supplementary Table S1.

2.6. Microneutralization tests against SFTSV

Patient serum samples were serially diluted (from 1:8 to 1:128) in DMEM containing 2% FBS and incubated with 100 TCID₅₀ SFSTV for each test at 37 °C for 1 h. The virus-serum mixture was added to Vero cells (10⁴ cells/well) seeded in the 96-well plates and incubated at 37 °C for 72 h. IFAs were performed to visualize SFTSV infection in each well. The neutralization titers were expressed as the reciprocal of the highest dilution that prevents SFTSV infection in three replicates.

2.7. Statistical analysis

Statistical analyses were performed using GraphPad Prism (Version 8, San Diego, California) and IBM SPSS Statistics (Version 19, Chicago). P values less than 0.05 were considered statistically significant.

3. Result

3.1. LIPS assay was established based on SFTSV-NP expression

Seroalogical responses to SFTSV were investigated in all 464 patients by LIPS assay. The method was established based on the expression of SFTSV nucleoprotein (NP), and was validated by both IFAs and Western blot which detected the successful expression of SFTSV NP in fusion with Flag-tag in the plasmid-transfected cells (Fig. 1A and B). Subsequently, serial dilutions of the polyclonal rabbit antibody against anti-SFTSV NP were used to demonstrate the feasibility of LIPS to determine antibody levels. The amount of Renilla luciferase (Rluc)-NP-antibody complex captured by protein A/G in each test was measured and presented in the form of Rluc light units (LU). As expected, the dilutions containing decreased levels of anti-SFTSV NP antibody binding to SFTSV NP was detected in a concentration-dependent manner (Fig. 1C).

3.2. SFTSV infection was identified from a few of febrile patients in Shaoxing

SFTSV infection was suspected among the 464 febrile patients from Shaoxing City, including 251 men (54.1%) and 213 women (45.9%), especially among those samples collected during the peak season of tick activity. Demographic and clinical characteristics of the 464 febrile patients were summarized in Table 1. The median age of these patients is 65 with the interquartile range (IQR) from 54 to 76. The counts of platelets (PLT) and white blood cells (WBC) of 80 patients were obtained from the cases identified with serological response to SFTSV by LIPS, the median and IQR of which were at respective normal ranges of PLT and WBC. Serum samples from the 223 febrile patients collected from April to June were used to detect SFTSV infection by qRT-PCR. The results showed that 16 (3.4%) of the 464 samples were positive for SFTSV RNA (Table 1), with the virus load ranging from 1.13 × 10⁴ to 1.83 × 10⁵ copies/mL in sera (Table 2), which suggested the 16 patients had SFTSV viremia and revealed the occurrence of SFTSV infection in Shaoxing. Detection of the other 241 samples for SFTSV RNA was not performed due to the sample limits.

3.3. Positive serological response to SFTSV was found among the febrile patients in Shaoxing City

Antibody responses to SFTSV were subsequently investigated in the febrile patient serum samples using LIPS. In total, 82 (17.7%) cases of the 464 patients had a positive serological response to SFTSV (Table 1), including 47 male (10.1%) and 35 female (7.5%) (Supplementary Table S1). Fifty-six patients (12.1%) were >60 years of age, suggesting a significantly high SFTS incidence among the elderly (P < 0.001) (Supplementary Table S1). In addition, the specificity of this method was...
| Time of collection | Sample | Viral loads (copies/mL) | Anti SFTSV | MNT (Titer) | Diagnosis | Other pathogen testing | Leukopenia | Thrombocytopenia |
|-------------------|--------|-------------------------|------------|-------------|-----------|------------------------|-----------|-----------------|
| April to June     | A4     | 10.09                   | +          | -           | 24†       | Infectious fever        | -         | -               |
|                   | A10    | 5.09                    | +          | +           | -         | Digestive disease       | -         | -               |
|                   | A20    | 2.88                    | -          | +           | 24†       | N/A                    | N/A       | -               |
|                   | A27    | 2.71 × 10^6             | 1.39       | +           | +         | Respiratory disease     | -         | 2.78 × 10^9/L   |
|                   | A30    | 8.28 × 10^6             | 1.05       | +           | +         | Respiratory disease     | -         | 3.32 × 10^9/L   |
|                   | A31    | -                       | 7.36       | +           | +         | Infectious fever        | -         | 2.55 × 10^9/L   |
|                   | A39    | -                       | 2.32       | +           | +         | Respiratory disease     | N/A       | 94 × 10^9/L     |
|                   | A48    | -                       | 3.25       | +           | +         | Respiratory disease     | N/A       | -               |
|                   | A50    | -                       | 1.06       | +           | +         | Respiratory disease     | -         | -               |
|                   | A54    | 4.98 × 10^6             | 1.09       | -           | +         | Fever of unknown origin | -         | -               |
|                   | A57    | 9.51 × 10^6             | 1.52       | +           | -         | 24†                    | -         | -               |
|                   | A70    | -                       | 1.19       | +           | -         | N/A                    | -         | -               |
|                   | A73    | -                       | 1.07       | +           | -         | Infectious fever        | -         | 78 × 10^9/L     |
|                   | A77    | -                       | 7.20       | +           | -         | Infectious fever        | -         | 71 × 10^9/L     |
|                   | A81    | -                       | 13.47      | +           | -         | Influenza A+            | -         | 2.63 × 10^9/L   |
|                   | A82    | -                       | 6.47       | +           | -         | Other disease           | -         | -               |
|                   | A88    | -                       | 1.01       | +           | -         | Influenza fever          | -         | 3.29 × 10^9/L   |
|                   | A99    | 9.28                    | +          | +           | -         | Other disease           | -         | -               |
|                   | A94    | -                       | 1.47       | +           | +         | Other disease           | -         | -               |
|                   | A97    | 18.13                   | -          | +           | 24†       | Respiratory disease     | -         | -               |
|                   | A113   | -                       | 1.25       | +           | -         | Respiratory disease     | -         | -               |
|                   | A117   | -                       | 25.05      | +           | -         | Other disease           | -         | -               |
|                   | A119   | -                       | 4.24       | +           | +         | Severe                  | 68 × 10^9/L | -               |
|                   | A128   | -                       | 13.19      | -           | +         | 24†                    | -         | -               |
|                   | A134   | -                       | 1.31       | -           | +         | 24†                    | Other disease | -               |
|                   | A139   | -                       | 1.36       | +           | +         | N/A                    | N/A       | -               |
|                   | A141   | -                       | 1.28       | +           | -         | N/A                    | N/A       | -               |
|                   | A146   | -                       | 2.66       | +           | -         | N/A                    | N/A       | -               |
|                   | A147   | -                       | 1.37       | +           | +         | N/A                    | N/A       | -               |
|                   | A148   | -                       | 1.36       | +           | +         | Respiratory disease     | N/A       | -               |
|                   | A153   | -                       | 1.41       | +           | +         | N/A                    | N/A       | -               |
|                   | A154   | -                       | 1.43       | +           | +         | N/A                    | N/A       | -               |
|                   | A155   | -                       | 38.05      | +           | +         | 24†                    | Hemophagocytic syndrome | -         | 68 × 10^9/L     |
|                   | A165   | -                       | 1.01       | -           | +         | Infectious fever        | -         | 2.38 × 10^9/L   |
|                   | A169   | -                       | 14.58      | +           | +         | 24†                    | N/A       | N/A             |
|                   | A174   | -                       | 3.24       | -           | +         | N/A                    | N/A       | -               |
|                   | A177   | -                       | 1.74       | +           | +         | N/A                    | N/A       | -               |
|                   | A181   | -                       | 12.19      | +           | -         | N/A                    | N/A       | -               |
|                   | A185   | -                       | 3.99       | -           | +         | N/A                    | N/A       | -               |
|                   | A192   | -                       | 2.95       | +           | +         | N/A                    | N/A       | -               |
|                   | A195   | -                       | 1.02       | +           | +         | N/A                    | N/A       | -               |
|                   | A197   | -                       | 12.98      | +           | +         | N/A                    | N/A       | -               |
|                   | A198   | -                       | 1.22       | +           | +         | N/A                    | N/A       | -               |
|                   | A199   | -                       | 1.63       | +           | +         | Respiratory disease     | -         | -               |
|                   | A209   | 2.94 × 10^6             | 1.86       | +           | -         | 24†                    | Respiratory disease | -         | -               |
|                   | A210   | -                       | 1.00       | -           | +         | N/A                    | N/A       | -               |
|                   | A211   | -                       | 2.61       | -           | -         | Infection fever         | -         | 96 × 10^9/L     |
|                   | A214   | -                       | 6.35       | +           | +         | N/A                    | N/A       | -               |
|                   | A219   | -                       | 1.26       | +           | +         | N/A                    | N/A       | -               |
|                   | A6     | 2.08 × 10^6             | <1         | N/A         | N/A       | Respiratory disease     | -         | -               |
|                   | A18    | 2.57 × 10^6             | <1         | N/A         | N/A       | Influenza A+            | N/A       | -               |
|                   | A29    | 4.01 × 10^6             | <1         | N/A         | N/A       | Other disease           | -         | -               |
|                   | A37    | 3.37 × 10^6             | <1         | N/A         | N/A       | Other disease           | -         | 3.3 × 10^9/L    |
|                   | A41    | 4.01 × 10^6             | <1         | N/A         | N/A       | Fever of unknown origin | -         | -               |
|                   | A65    | 4.88 × 10^6             | <1         | N/A         | N/A       | Heart disease           | -         | -               |
|                   | A104   | 1.83 × 10^7             | <1         | N/A         | N/A       | Infectious fever        | -         | -               |
|                   | A130   | 3.53 × 10^6             | <1         | N/A         | N/A       | Heart disease           | -         | -               |
|                   | A160   | 2.74 × 10^6             | <1         | N/A         | N/A       | Respiratory disease     | -         | -               |
|                   | A162   | 1.13 × 10^6             | <1         | N/A         | N/A       | Severe                  | 4.08 × 10^9/L | 73 × 10^9/L    |
|                   | A187   | 3.44 × 10^6             | <1         | N/A         | N/A       | Respiratory disease     | -         | -               |
|                   | Subtotal| 60                      | 16         | 49          | 23        | 37                     | 9         | 8               |
| August to October | B6     | N/A                     | 2.49       | +           | +         | Infectious fever        | -         | 1.23 × 10^6/L   |
|                   | B9     | N/A                     | 1.54       | +           | +         | Respiratory disease     | -         | 3.89 × 10^9/L   |
|                   | B12    | N/A                     | 5.15       | +           | +         | Respiratory disease     | -         | -               |

(continued on next page)
validated by using serum samples from 10 febrile patients confirmed with antibody response to TAMV. The results showed that these samples did not have significant reaction with SFTSV antigen. Thirty serum samples from healthy donors were also included as healthy control (Fig. 2). These findings were further supported by the IFA results involving 82 LIPS-positive serum samples, 10 randomly selected LIPS-negative samples, and samples from two healthy donors. Sixty-eight of the 82 LIPS-positive serum samples tested positive for anti-SFTSV by IFAs, a confirmation rate of 82.9%. The IFA-positive samples included 14 samples with an IgM only response, 32 with IgG, and 22 with both (Table 2, Supplementary Fig. S1). As expected, the IFA results were negative for the LIPS-negative samples and healthy donor samples (Supplementary Fig. S1). Moreover, in microneutralization tests, 11 of the 82 LIPS-positive serum samples including seven men and four women, had neutralizing antibodies to SFTSV with the neutralizing titers ranging from $2^2$ to $2^8$ (Tables 1 and 2). These results further suggest that SFTSV infections had occurred in Shaoxing in 2019, despite the limited number of collected febrile patients.

### 3.4. Epidemiologic characteristics and records of clinical diagnosis suggested missed cases of SFTS

The epidemiologic characteristics with respected to age, gender, underlying disease, days post illness onset, and sampling time were analyzed based on the LU values of each sample, which could represent the levels of total antibodies against SFTSV (Table 3). The patients of 21–40 years old and 41–60, and those aged over 60 had comparable levels of antibody response to SFTSV. This was also observed among the male and female patients. Since 12.1% patients were over 60 years old, their comorbidities may affect the levels of antibody response. Of the 60 LIPS-positive cases, 27 cases had underlying diseases, including hypertension (8, 29.7%), chronic respiratory diseases (9, 33.3%), coronary heart disease (2, 7.4%), metabolic diseases (1, 3.7%), and others (7, 25.9%) (Table 3). The patients with comorbidities had levels of antibody against SFTSV significantly lower than those without ($P = 0.0113$). The antibody levels could change during different time of sample collection post illness onset (Infectious time). However, this change was not

---

**Table 2 (continued)**

| Time of collection | Sample | Viral loads$^a$ (copies/mL) | Anti SFTSV | MNT (Titer)$^d$ | Diagnosis$^c$ | Other pathogen testing$^f$ | Leukopenia$^b$ | Thrombocytopenia$^b$ |
|--------------------|--------|-----------------------------|------------|-----------------|---------------|-----------------------------|----------------|---------------------|
|                    |        |                             | LIPS$^e$  | IFA- IgM$^e$ | IFA- IgG$^e$ | Infectious fever            | Dengue virus$^+$ | $1.38 \times 10^5$L |
| B21                | N/A    | 1.03                        | +          | -               | -             | N/A                         | 89 $\times 10^9$/L |                     |
| B24                | N/A    | 1.43                        | -          | +               | +             | Respiratory disease         | -               |                     |
| B26                | N/A    | 1.59                        | +          | +               | -             | Infectious fever            | -               |                     |
| B29                | N/A    | 2.00                        | +          | +               | -             | respiratory disease         | 2.49 $\times 10^9$/L |                     |
| B31                | N/A    | 1.11                        | -          | +               | -             | Other disease               | -               |                     |
| B37                | N/A    | 3.99                        | +          | -               | 2$^2$         | Respiratory disease         | Dengue virus$+$ | $1.38 \times 10^5$L |
| B44                | N/A    | 2.48                        | +          | +               | -             | Respiratory disease         | -               |                     |
| B45                | N/A    | 3.93                        | +          | -               | -             | Respiratory disease         | -               |                     |
| B47                | N/A    | 1.08                        | +          | -               | -             | Respiratory disease         | -               |                     |
| B54                | N/A    | 1.33                        | -          | +               | -             | Respiratory disease         | -               |                     |
| B61                | N/A    | 2.70                        | -          | +               | -             | Respiratory disease         | -               |                     |
| B62                | N/A    | 1.48                        | -          | +               | -             | Respiratory disease         | -               |                     |
| B68                | N/A    | 1.52                        | -          | +               | -             | Other disease               | -               |                     |
| B74                | N/A    | 15.52                       | +          | -               | 2$^2$         | Infectious fever            | -               |                     |
| B79                | N/A    | 10.52                       | -          | -               | -             | Neurological and digestive  | -               |                     |
| B87                | N/A    | 12.46                       | -          | -               | -             | Respiratory disease         | -               |                     |
| B93                | N/A    | 9.33                        | -          | -               | -             | Other disease               | -               |                     |
| B112               | N/A    | 5.81                        | -          | -               | -             | Respiratory disease         | -               |                     |
| B117               | N/A    | 3.23                        | -          | -               | -             | Infectious fever            | -               |                     |
| B142               | N/A    | 1.51                        | -          | -               | -             | Respiratory disease         | -               |                     |
| B147               | N/A    | 11.62                       | -          | -               | -             | Other disease               | -               |                     |
| B150               | N/A    | 1.80                        | +          | +               | -             | Other disease               | -               |                     |
| B183               | N/A    | 1.23                        | -          | +               | -             | Respiratory disease         | -               |                     |
| B190               | N/A    | 1.85                        | -          | -               | -             | Infectious fever            | -               | $87 \times 10^9$/L  |
| B206               | N/A    | 1.01                        | -          | -               | -             | Respiratory disease         | -               |                     |
| B210               | N/A    | 4.11                        | -          | -               | -             | Infectious fever            | -               |                     |
| B212               | N/A    | 1.53                        | -          | +               | -             | Other disease               | -               |                     |
| B215               | N/A    | 1.37                        | -          | +               | -             | Respiratory disease         | -               |                     |
| B221               | N/A    | 5.15                        | -          | -               | -             | Infectious fever            | -               | $3.93 \times 10^5$/L |
| B242               | N/A    | 2.84                        | +          | +               | -             | Respiratory disease         | -               |                     |
| **Subtotal**       | 33     | 33                          | 13         | 17              | 2             | 6                           | 4               | 15                  |
| **Total**          | 93     | 16                          | 82         | 36              | 54            | 11                          | 15              | 12                  |

---

$^a$ qRT-PCR was not performed to the samples collected from Aug to Oct due to sample limitations.

$^b$ The samples positive for anti-SFTSV antibodies as determined by LIPS were shown as the Light units (LU) fold changes above the cut-off value, while those negative were shown as “<1”.

$^c$ IgM and IgG response to SFTSV were detected by IFAs, which were not carried out for the LIPS-negative samples.

$^d$ Neutralization tests were not performed for the LIPS-negative samples.

$^e$ The diagnostic records available from 70 patients were listed.

$^f$ Records of other pathogen testing including blood culture testing, HIV, HBV, HCV, Treponema pallidum, Influenza A, Influenza B and epidemic hemorrhagic fever related pathogens.

$^g$ The normal range of WBC counts in healthy population is from $4 \times 10^9$ to $10 \times 10^9$/L. The counts less than the lower limit were shown, which may be considered leukopenia. The counts within the normal range were not listed.

$^h$ The normal range of PLT counts in healthy population is from $100 \times 10^9$ to $300 \times 10^9$/L. The counts less than the lower limit were shown, which may be considered thrombocytopenia. The counts within the normal range were not listed.
Moreover, we found that the LIPS-positive samples collected slightly increased in the samples collected three weeks after disease study, which is probably due to the sample limit, whereas the levels significantly higher than those collected during April to June, which is the peak season of tick activity, had antibody levels significantly higher than those collected during August to October (P = 0.0007) (Table 3). This suggested a potential relationship between the risk of SFTSV infection and tick activity and a high incidence of SFTS during April to June in Shaoxing City. SFTSV neutralizing activity may be associated with antibody levels. Eight patients (A4, A20, A97, A128, A155, A169, B37, and B74) with neutralizing antibodies had high total antibody levels (>2-fold above the cut-off value), despite the correlation was not observed in the significant manner (Table 2).

The diagnostic records of 70 patients were reviewed, including 16 patients with viremia and 60 LIPS-positive patients (Table 2). None of these patients were diagnosed with SFTS, although twenty-two patients had leukaemia, thrombocytopenia, or both (22/70, 31.4%). These patients were mostly diagnosed with respiratory diseases (31/70, 44.3%), followed by infectious fever or fever of unknown origin (17/70, 24.3%), heart diseases (2/70, 2.9%), digestive diseases (2/70, 2.9%), severe thrombocytopenia (2/70, 2.9%), neurological diseases (1/70, 1.4%), and hemophagocytic syndrome (1/70, 1.4%). The other 14 patients (19.7%) were diagnosed with other diseases. Therefore, we speculate that there could be missed SFTS cases among these febrile patients according to the above results of laboratory tests.

4. Discussion

SFTS epidemics remain an important public health threat in Zhejiang Province, as for the top fifth high incidence of SFTS and the higher average case fatality rate than other provinces in China (Sun et al., 2017; Wu et al., 2020). The epidemic features of SFTS in Zhejiang from 2011 to 2016 showed that the number of SFTS cases and affected counties increased year by year, with over 50% of the cases reported from April to June and 13.8% of the cases from August to October (Sun et al., 2017). During 2011–2018, there were 37 counties in Zhejiang reporting SFTS cases, about 74% of which were from seven counties locating in Zhushan County (Daishan), Taizhou City (Linhai, Tianai, and Sannen), Ningbo City (Ninghai and Xiangshan), and Hangzhou City (Chun’an), respectively. Shaoxing City, located in the eastern area of Zhejiang Province, was not included in any of the top eleven counties with the highest total incidence of SFTS (Wu et al., 2020). Moreover, from 2011 to 2018, very a few cases (<10) were reported from Shaoxing (only from Shangyu District) according to the records in China Information System for Diseases Control and Prevention (Wu et al., 2020). These data suggest that Shaoxing was not the major area affected by SFTS.

According to the guidelines issued by the National Health Commission of the People’s Republic of China, SFTSV infection could be confirmed in terms of identification of viral RNA and antibody response in laboratory, which is important for the clinical diagnosis. LIPS assay is known to be highly sensitive for evaluating total antibody responses to specific antigens. It has been primarily developed for the diagnosis of autoimmune disease (Maeda et al., 2017) and later expanded for the laboratory detection of serological responses to parasites (Matsumoto et al., 2019) and viral pathogens, such as Pteropine orthoreovirus (Uiëhara et al., 2019) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Chia et al., 2020). LIPS was developed for serological tests for SFTSV in Japan recently (Matsumoto et al., 2018; Matsu et al., 2021). It was firstly established on the basis of glycoprotein expression to detect antibody against SFTSV among over 3000 blood donors in an SFTS endemic area in Japan. However, no positive cases were identified, probably because, on one hand, all tested samples were from healthy blood donors who were unlikely to be exposed to SFTSV, and on the other hand, the results might be affected by the use of viral antigen (Matsumoto et al., 2018). The recent study reported the establishment of LIPS based on SFTSV-NP, which was used to investigate the seroprevalence of SFTSV among animals in Japan. The results showed sero-positive rates of anti-SFTSV antibody for cats, dog, wild boars and deer were 1.9%, 9.6%, 53.9%, and 34.7%, respectively, suggesting a high risk of SFTSV exposure among animals (Matsu et al., 2021).

Table 3

Analysis of the correlations of gender, age, comorbidities, days post illness onset, and sampling time with levels of antibodies against SFTSV.

| Factor                        | Antibody levels | P value |
|-------------------------------|-----------------|---------|
| Gender                        |                 |         |
| Male (n = 47)                 | 10.8 (5.80–20.1)| 0.9554  |
| Female (n = 35)               | 8.32 (5.65–32.8)|         |
| Age                           |                 |         |
| 21–40 (n = 13)                | 11.0 (5.69–41.8)| 0.6961  |
| 41–60 (n = 13)                | 9.62 (5.15–26.8)|         |
| ≥61 (n = 56)                  | 6.22 (5.88–12.2)|         |
| Comorbidities a               |                 |         |
| Yes (n = 27)                  | 6.84 (5.42–12.4)| 0.0113  |
| No (n = 33)                   | 19.0 (7.09–41.8)|         |
| Days post illness onset       |                 |         |
| 1–7 (n = 46)                  | 12.7 (8.73–26.9)| 0.8436  |
| 8–14 (n = 8)                  | 12.6 (8.83–26.7)|         |
| 15–21 (n = 12)                | 12.4 (6.96–35.4)|         |
| >21 (n = 10)                  | 19.2 (10.8–48.5)|         |
| Month of sampling             |                 |         |
| April to June (n = 45)        | 15.4 (10.4–61.0)| 0.0007  |
| August to October (n = 20)    | 8.45 (6.08–18.3)|         |

IQR, interquartile range.

a Among the LIPS-positive group, 60 cases had comorbidities including hypertension, chronic respiratory diseases, coronary heart disease, metabolic diseases, and endocrine diseases.
Here in this study, we identified cases having infection of SFTSV or exposure to SFTSV among the febrile patients in 2019. In total, 82 (17.1%) of the 464 patients were found having antibody response to SFTSV antigen with LIPS assay, which was further confirmed by IFAs with a positive rate of 82.9% (68/82). This difference could be attributed to the use of protein A/G by LIPS to capture the antibody-SFTSV NP complex, which could recognize almost all types of human antibodies, including all IgG subclasses, IgA, IgE, IgM, and IgD to a lesser extent (Eliasson et al., 1989; Burbelo et al., 2010), whereas the antibody reaction to viral antigen could only be distinguished in separate tests of IFA by using anti-IgM or -IgG secondary antibody. So, LIPS assay may be more sensitive than IFAs, as the LU values from each test reflect the levels of total antibody response. LIPS is also sensitive for detecting various animal antibodies (Burbelo et al., 2011; Matsu et al., 2021). This was also demonstrated by the tests for the serial dilutions of rabbit polyclonal antibody anti-SFTSV-NP in the current study. Moreover, the LIPS results revealed the antibody reaction specificity to SFTSV, as serum samples from patients having antibody against TAMV did not show cross-reaction with SFTSV. Despite infection of influenza virus (4, 5.7%), parainfluenza virus (1, 1.4%), and dengue virus (1, 1.4%) were found from 6 of the 70 patients with available diagnostic records, they were confirmed having SFTSV infection as evidenced by the results from qRT-PCR, IFA, or neutralization assay (Table 2). Therefore, together with the results from previous studies (Matsumoto et al., 2018; Matsu et al., 2021), LIPS could be developed to be an effective method in laboratory for the survey of total serological response to SFTSV among humans and animals. In addition, the results by LIPS revealed that there had been substantial occurrence of SFTS in Shaoxing in 2019 and indicated threats to public health, although it is not a major epidemic area of SFTS.

Moreover, the results of qRT-PCR and neutralization assays showed that at least 26 cases had SFTSV infection or exposure to SFTSV, including 15 patients with viremia, 10 patients with neutralizing antibodies, and one with both (Table 2). However, none of these febrile patients were diagnosed SFTS, which could be attributed to their mild manifestations. Not all of SFTSV patients would have the typical symptoms like leukopenia and thrombocytopenia. Among 286 confirmed SFTS cases from eastern China, 75.5% cases had leukopenia and 66.8% cases had thrombocytopenia (Li et al., 2017). A recent study reported an estimated rate of missed SFTS diagnosis at 8.3%, suggesting a higher incidence of SFTS than that currently reported (Huang et al., 2018). The study also suggested that missed cases could be identified based on high IgG titers and IgM response to SFTSV (Huang et al., 2018). Therefore, we speculate that at least the 26 cases were miss-diagnosed of SFTS probably due to their subclinical manifestation of the SFTS symptoms. According to the serological evidence resulted from LIPS assay, the other 56 patients also had exposure to SFTSV. The use of serological detection methods may promote a more accurate diagnosis and laboratory confirmation of SFTS.

In summary, the current study established a LIPS assay based on SFTSV NP expression for serological detection of anti-SFTSV antibodies and determined the levels of antibody response in febrile patients. The results demonstrated the occurrence of SFTSV infection in patients from Shaoxing City of Zhejiang Province and suggested a higher incidence of SFTS than that previously reported. The findings further demonstrated that LIPS may provide an alternative strategy to confirm SFTSV infection in the laboratory.

Data availability

All the data generated during the current study are included in the article.

Ethics statement

The study was reviewed and approved for ethical consideration by the institutional review board (IRB) of Wuhan Institute of Virology, CAS. (Approval Number: WIVH33202102). All patients enrolled in the study were from Shaoxing People’s Hospital. Written informed consent was provided by all participants.

Author contributions

Shengyao Chen: conceptualization, formal analysis, investigation, data curation, visualization, writing - original draft, writing - review & editing. Minjun Xu: data curation, investigation, methodology. Xiaoli Wu: data curation, visualization, methodology. Yuan Bai: data curation, investigation. Junming Shi: data curation. Min Zhou: methodology, resources. Qiaoli Wu: methodology, resources. Shuang Tang: methodology. Fei Deng: conceptualization, funding acquisition, project administration, resources, supervision, writing - review & editing. Bo Qin: conceptualization, resources, data curation. Shu Shen: conceptualization, resources, funding acquisition, project administration, supervision, writing - original draft, writing - review & editing.

Conflict of interest

The authors declare that they have no conflict of interest.

Acknowledgements

We would like to thank Prof. Linfa Wang from Duke - National University of Singapore Medical College and Prof. Peng Zhou from Wuhan institute of Virology for kindly providing the pREN2 plasmid and the technical support to establish LIPS. We would like to thank all team members of the National Virus Resource Center for the preserving and providing human serum samples used for experiment. We thank Mr. Zhang Zhong for assisting cell culture and Mr. Xijia Liu for antibody preparation. This work was supported by the National Program on Key Research Project of China (2018YFE0020400, 2019YFC1200700), the National Natural Science Foundation of China (U20A20135), the Strategic Biological Resources Capacity Building Project of Chinese Academy of Sciences (KEF-BRP-017-06), and the Key deployment projects of Chinese Academy of Sciences (KJZD-SW-L11).

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.virol.2022.01.018.

References

Burbelo, P.D., Bren, K.E., Ching, K.H., Coleman, A., Yang, X., Kariu, T., Iadarola, M.J., Pal, U., 2011. Antibody profiling of Borrelia burgdorferi infection in horses. Clin. Vaccine Immunol. 18, 1562-1567.
Burbelo, P.D., Ching, K.H., Bush, E.R., Han, B.L., Iadarola, M.J., 2010. Antibody-profiling technologies for studying humoral responses to infectious agents. Expert Rev. Vaccines 9, 567-578.
Burbelo, P.D., Iadarola, M.J., Chaturvedi, A., 2019. Emerging technologies for the detection of viral infections. Future Virol. 14, 39-49.
Burbelo, P.D., Lebovitz, E.E., Notkins, A.L., 2015. Luciferase immunoprecipitation systems for measuring antibodies in autoimmune and infectious diseases. Transl. Res. 165, 325-335.
Chia, W.N., Tan, C.W., Foo, R., Kang, A.E.Z., Peng, Y., Sivalingam, V., Tiu, C., Ong, X.M., Zhu, F., Young, B.E., Chen, M.I., Tan, Y.J., Lye, D.C., Anderson, D.E., Wang, L.F., 2020. Serological differentiation between COVID-19 and SARS infections. Emerg. Microb. Infect. 9, 1497-1505.
Eliasson, M., Anderson, R., Olson, A., Wiggzell, H., Uhlen, M., 1989. Differential IgG-binding characteristics of staphylococcal protein A, streptococcal protein G, and a chimeric protein AG. J. Immunol. 142, 575-581.
Huang, X., Li, L., Li, L., Li, A., Wang, S., Li, D., 2021. Epidemiological characteristics of severe fever with thrombocytopenia syndrome from 2010 to 2019 in Mainland China. Int. J. Environ. Res. Publ. Health 18, 3092.
Huang, X., Wang, S., Wang, X., Lyu, Y., Jiang, M., Chen, D., Li, K., Liu, J., Xie, S., Lyu, T., Sun, J., Xu, P., Cao, M., Liang, M., Li, D., 2018. Estimation of the incidence of severe fever with thrombocytopenia syndrome in high endemic areas in China: an inpatient-based retrospective study. BMC Infect. Dis. 18, 66.
Li, Z., Hu, J., Cai, L., Hong, Y., Liu, J., Li, P., Guo, X., Liu, W., Wang, X., Qi, X., Wu, B., Feng, Z., Shen, A., Liu, X., Zhao, H., Tan, W., Zhou, J., Xing, Z., Bao, C., 2017.
Increased prevalence of severe fever with thrombocytopenia syndrome in eastern China clustered with Multiple genotypes and reasserted virus during 2010-2015. Sci. Rep. 7, 6503.

Maeda, Y., Nakane, S., Higuchi, O., Nakamura, H., Komori, A., Migita, K., Mukaino, A., Umeda, M., Ichinose, K., Tamai, M., Kawashiri, S.Y., Sakai, W., Yatsuhashi, H., Kawakami, A., Matsuo, H., 2017. Ganglionic acetylcholine receptor autoantibodies in patients with autoimmune diseases including primary biliary cirrhosis. Mod. Rheumatol. 27, 664–668.

Matsuno, C., Shinozuru, N., Furuta, R.A., Tanishige, N., Shimojima, M., Matsuyabayashi, K., Nagai, T., Tsubaki, K., Satake, M., 2018. Investigation of antibody to severe fever with thrombocytopenia syndrome virus (SFTSV) in blood samples donated in a SFTS-endemic area in Japan. Vox Sang. 113, 297–299.

Matsu, A., Hamakubo, E., Yabuki, M., 2021. Serorevalence of severe fever with thrombocytopenia syndrome virus in animals in Kagoshima Prefecture, Japan, and development of Gaussia luciferase immunoprecipitation system to detect specific IgG antibodies. Ticks Tick Borne Dis 12, 101771.

Matsuo, A., Yokota, S.I., Ito, K., Masatani, T., 2017. Serorevalence of toxoplasma gondii in free-ranging and feral cats on Amami Oshima Island, Japan. J. Vet. Med. Sci. 79, 1853–1856.

Moming, A., Shen, S., Fang, Y., Zhang, J., Zhang, Y., Tang, S., Li, T., Hu, Z., wang, H., Zhang, Y., Wang, L., Sun, S., Deng, F., 2021. Evidence of human exposure to Tanday virus, Northwestern China. Emerg. Infect. Dis. (in press).

Shen, S., Duan, X., Wang, B., Zhu, L., Zhang, Y., Zhang, J., Wang, J., Luo, T., Kou, C., Liu, D., Lx, C., Zhang, L., Chang, C., Su, Z., Tang, S., Qiao, J., Moming, A., Wang, C., Abudurexiti, A., Wang, H., Hu, Z., Zhang, Y., Sun, S., Deng, F., 2018. A novel tick-borne phlebovirus, closely related to severe fever with thrombocytopenia syndrome virus and Heartland virus, is a potential pathogen. Emerg. Microb. Infect. 7, 95.

Sun, J., Lu, L., Wu, H., Yang, J., Ren, J., Liu, Q., 2017. The changing epidemiological characteristics of severe fever with thrombocytopenia syndrome in China, 2011-2016. Sci. Rep. 7, 9326.

Uehara, A., Tan, C.W., Mani, S., Chua, K.B., Leo, Y.S., Anderson, D.E., Wang, L.F., 2019. Serological evidence of human infection by bat orthoreovirus in Singapore. J. Med. Virol. 91, 707–710.

Wu, H., Wu, C., Lu, Q., Ding, Z., Xue, M., Lin, J., 2020. Spatial-temporal characteristics of severe fever with thrombocytopenia syndrome and the relationship with meteorological factors from 2011 to 2018 in Zhejiang Province, China. PLoS Neglected Trop. Dis. 14, e0008186.

Xiong, S., Zhang, W., Li, M., Xiong, Y., Li M., Wang, H., Yang, D., Peng, C., Zheng, X., 2016. A simple and practical score model for predicting the morality of severe fever with thrombocytopenia syndrome patients. Medicine (Baltim.) 95, e5708.

Yu, K.J., Liang, M.F., Zhang, S.Y., Liu, Y., Li, J.D., Sun, Y.L., Zhang, L., Zhang, Q.F., Popov, V.I., Li, C., Ou, J., Li, Q., Zhang, Y.P., Hai, R., Wu, W., Wang, Q., Zhan, F.X., Wang, X.J., Kan, B., Wang, S.W., Wan, K.L., Jing, H.Q., Lu, J.X., Yin, W.W., Zhou, H., Guan, X.H., Liu, J.F., Bi, Z.Q., Liu, G.H., Ren, J., Wang, H., Zhao, Z., Song, J.D., He, J.R., Wan, T., Zhang, J.S., Pu, X.P., Sun, L.N., Dong, X.P., Feng, Z.J., Yang, W.Z., Hong, T., Zhang, Y., Walker, D.H., Wang, Y., Li, D.X., 2011. Fever with thrombocytopenia associated with a novel bunyavirus in China. N. Engl. J. Med. 364, 1523–1532.

Zhang, Y., Shen, S., Shi, J., Su, Z., Li, M., Zhang, W., Li, M., hu, Z., peng, C., zheng, X., Deng, F., 2017. Isolation, characterization, and phylogenetic analysis of three new severe fever with thrombocytopenia syndrome bunyavirus strains derived from Henan Province, China. Virol. Sin. 32, 89–96.

Zhu, L., Yin, F., Moming, A., Zhang, J., Wang, B., Gao, L., Ruan, J., Wu, Q., Wu, N., Wang, H., Deng, F., Lu, G., Shen, S., 2019. First case of laboratory-confirmed severe fever with thrombocytopenia syndrome disease revealed the risk of SFTSV infection in Xinjiang, China. Emerg. Microb. Infect. 8, 1122–1125.